dc.contributor.author | Freund, Y | en_US |
dc.contributor.author | Bloom, B | en_US |
dc.contributor.author | Bokobza, J | en_US |
dc.contributor.author | Baarir, N | en_US |
dc.contributor.author | Laribi, S | en_US |
dc.contributor.author | Harris, T | en_US |
dc.contributor.author | Navarro, V | en_US |
dc.contributor.author | Bernard, M | en_US |
dc.contributor.author | Pearse, R | en_US |
dc.contributor.author | Riou, B | en_US |
dc.contributor.author | Hausfater, P | en_US |
dc.contributor.author | BISTRO Investigators | en_US |
dc.date.accessioned | 2016-01-29T16:04:32Z | |
dc.date.available | 2015-02-20 | en_US |
dc.date.issued | 2015 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/10968 | |
dc.description.abstract | OBJECTIVE: To evaluate the performance of S100-B protein and copeptin, in addition to clinical variables, in predicting outcomes of patients attending the emergency department (ED) following a seizure. METHODS: We prospectively included adult patients presented with an acute seizure, in four EDs in France and the United Kingdom. Participants were followed up for 28 days. The primary endpoint was a composite of seizure recurrence, all-cause mortality, hospitalization or rehospitalisation, or return visit in the ED within seven days. RESULTS: Among the 389 participants included in the analysis, 156 (40%) experienced the primary endpoint within seven days and 195 (54%) at 28 days. Mean levels of both S100-B (0.11 μg/l [95% CI 0.07-0.20] vs 0.09 μg/l [0.07-0.14]) and copeptin (23 pmol/l [9-104] vs 17 pmol/l [8-43]) were higher in participants meeting the primary endpoint. However, both biomarkers were poorly predictive of the primary outcome with a respective area under the receiving operator characteristic curve of 0.57 [0.51-0.64] and 0.59 [0.54-0.64]. Multivariable logistic regression analysis identified higher age (odds ratio [OR] 1.3 per decade [1.1-1.5]), provoked seizure (OR 4.93 [2.5-9.8]), complex partial seizure (OR 4.09 [1.8-9.1]) and first seizure (OR 1.83 [1.1-3.0]) as independent predictors of the primary outcome. A second regression analysis including the biomarkers showed no additional predictive benefit (S100-B OR 3.89 [0.80-18.9] copeptin OR 1 [1.00-1.00]). CONCLUSION: The plasma biomarkers S100-B and copeptin did not improve prediction of poor outcome following seizure. Higher age, a first seizure, a provoked seizure and a partial complex seizure are independently associated with adverse outcomes. | en_US |
dc.format.extent | e0122405 - ? | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | PLoS One | en_US |
dc.rights | © 2015 Freund et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited | |
dc.subject | Adult | en_US |
dc.subject | Cohort Studies | en_US |
dc.subject | Emergency Service, Hospital | en_US |
dc.subject | Endpoint Determination | en_US |
dc.subject | Female | en_US |
dc.subject | Glycopeptides | en_US |
dc.subject | Hospitalization | en_US |
dc.subject | Humans | en_US |
dc.subject | Internationality | en_US |
dc.subject | Male | en_US |
dc.subject | Predictive Value of Tests | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Recurrence | en_US |
dc.subject | S100 Calcium Binding Protein beta Subunit | en_US |
dc.subject | Seizures | en_US |
dc.title | Predictive value of S100-B and copeptin for outcomes following seizure: the BISTRO International Cohort Study. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1371/journal.pone.0122405 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/25849778 | en_US |
pubs.issue | 4 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published online | en_US |
pubs.volume | 10 | en_US |
dcterms.dateAccepted | 2015-02-20 | en_US |